Companion diagnostics sit at the intersection of pharma and device regulation, requiring simultaneous navigation of FDA CDx approval, therapeutic alignment, clinical evidence coordination, and a reimbursement landscape that remains unpredictable. CDx programs must co-develop with therapeutic partners on different timelines, meet different evidence standards, and satisfy different payer requirements — all while maintaining the technical precision that diagnostic accuracy demands.
Behavior Labs delivers lifecycle decision intelligence for precision diagnostics and companion diagnostic programs — connecting CDx regulatory pathway analysis, pharma partnership intelligence, clinical co-development strategy, and diagnostic reimbursement modeling into a platform that manages the unique complexity of developing a product whose success depends on another product's success.
CDx development is uniquely complex because it requires coordinating two product lifecycles — the therapeutic and the diagnostic — across different regulatory frameworks, different evidence standards, different commercial models, and different organizational structures. The platform manages this complexity systematically.
Navigate the dual regulatory landscape — PMA for the diagnostic, NDA/BLA for the therapeutic. Analyze FDA CDx approval precedents, co-development submission strategies, and the timing synchronization required to achieve simultaneous approval.
Map the CDx partnership landscape — which pharma programs need companion diagnostics, which biomarker strategies create the strongest differentiation, and how to position your diagnostic platform for maximum partnership value across multiple therapeutic programs.
Design the evidence generation strategy that satisfies both therapeutic and diagnostic regulatory requirements. Model biomarker validation timelines, analytical validation requirements, and clinical utility evidence needs in coordination with therapeutic program milestones.
Navigate the unique reimbursement landscape for precision diagnostics — CPT code assignment, CLFS pricing, ADLT designation, Medicare coverage pathways, and the evidence requirements that differ from therapeutic reimbursement. Model the economic case that supports sustainable pricing.
A rapidly growing market driven by biomarker-guided therapy adoption, regulatory evolution, and the expanding role of diagnostics in treatment selection.
See how lifecycle decision intelligence manages the unique coordination complexity of companion diagnostic development.
